Faculty Profiles - NISHIDA, Yoshihiro

デスモイド型線維腫症に対する放射線単独治療に関するシステマティックレビュー Reviewed

松延知哉, 国定俊之, 尾崎敏文, 岩本幸英, 西田佳弘

日本整形外科学会雑誌 Vol. 94 ( 3 ) page： S681 - S681 2020.3

Effects of ultraviolet irradiation with a LED device on bone metabolism associated with vitamin D deficiency in senescence-accelerated mouse P6 Reviewed Open Access

Morita D, Higuchi Y, Makida K, Seki T, Ikuta K, Ishiguro N, Nishida Y

Heliyon Vol. 6 ( 2 ) page： e03499 2020.2

Targetable driver mutations in multicentric reticulohistiocytosis. Reviewed International journal Open Access

Norihiro Murakami, Tomohisa Sakai, Eisuke Arai, Hideki Muramatsu, Daisuke Ichikawa, Shuji Asai, Yoshie Shimoyama, Naoki Ishiguro, Yoshiyuki Takahashi, Yusuke Okuno, Yoshihiro Nishida

Haematologica Vol. 105 ( 2 ) page： E61 - E64 2020.1

The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. Reviewed

Heng M, Gupta A, Chung PW, Healey JH, Vaynrub M, Rose PS, Houdek MT, Lin PP, Bishop AJ, Hornicek FJ, Chen YL, Lozano-Calderon S, Holt GE, Han I, Biau D, Niu X, Bernthal NM, Ferguson PC, Wunder JS; Japanese Musculoskeletal Oncology Group (JMOG, Nishida Y included); Soft Tissue Osteosarcoma International Collaborative (STOIC).

Eur J Cancer. Vol. 125 page： 130-141 2020.1

Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. Reviewed International journal Open Access

Yusuke Tsuda, Makoto Hirata, Kotoe Katayama, Toru Motoi, Daisuke Matsubara, Yoshinao Oda, Masashi Fujita, Hiroshi Kobayashi, Hirotaka Kawano, Yoshihiro Nishida, Tomohisa Sakai, Tomotake Okuma, Takahiro Goto, Koichi Ogura, Akira Kawai, Keisuke Ae, Ukei Anazawa, Yoshiyuki Suehara, Shintaro Iwata, Satoru Miyano, Seiya Imoto, Tatsuhiro Shibata, Hidewaki Nakagawa, Rui Yamaguchi, Sakae Tanaka, Koichi Matsuda

International journal of cancer Vol. 145 ( 12 ) page： 3276 - 3284 2019.12

Language：English Publishing type：Research paper (scientific journal)

Tenosynovial giant cell tumor (TSGCT) is a rare neoplasm. Although surgical resection is the widely accepted primary treatment for TSGCT, recurrences are frequent, and patients' joint function may be severely compromised. Previous studies reported that CSF1-COL6A3 fusion genes were identified in approximately 30% of TSGCTs. The aim of our study was to comprehensively clarify the genomic abnormalities in TSGCTs. We performed whole exome sequencing in combination with target sequence validation on 34 TSGCT samples. RNA sequencing was also performed on 18 samples. RNA sequencing revealed fusion transcripts involving CSF1, including novel CSF1-VCAM1, CSF1-FN1 and CSF1-CDH1 fusions, in 13/18 (72%) cases. These fusion genes were validated by chromogenic in situ hybridization. All CSF1 fusions resulted in the deletion of CSF1 exon 9, which was previously shown to be an important negative regulator of CSF1 expression. We also found that 12 (35%) of the 34 TSGCT samples harbored CBL missense mutations. All mutations were detected in exons 8 or 9, which encode the linker and RING finger domain. Among these mutations, C404Y, L380P and R420Q were recurrent. CBL-mutated cases showed higher JAK2 expression than wild-type CBL cases (p = 0.013). CSF1 fusion genes and CBL mutations were not mutually exclusive, and both alterations were detected in six of the 18 (33%) tumors. The frequent deletion of CSF1 exon 9 in the fusion transcripts suggested the importance of this event in the etiology of TSGCT. Our results may contribute to the development of new targeted therapies using JAK2 inhibitors for CBL-mutated TSGCT.

DOI： 10.1002/ijc.32421

MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis Reviewed

Integrated Exome and RNA Sequencing of Dedifferentiated Liposarcoma. Reviewed

Makoto Hirata, Naofumi Asano, Kotoe Katayama, Akihiko Yoshida, Yusuke Tsuda, Masaya Sekimizu, Sachiyo Mitani, Eisuke Kobayashi, Motokiyo Komiyama, Hiroyuki Fujimoto, Takahiro Goto, Yukihide Iwamoto, Norifumi Naka, Shintaro Iwata, Yoshihiro Nishida, Toru Hiruma, Hiroaki Hiraga, Hirotaka Kawano, Toru Motoi, Yoshinao Oda, Daisuke Matsubara, Masashi Fujita, Tatsuhiro Shibata, Hidewaki Nakagawa, Robert Nakayama, Tadashi Kondo, Seiya Imoto, Satoru Miyano, Akira Kawai, Rui Yamaguchi, Hitoshi Ichikawa, and Koichi Matsuda

Nat Commun Vol. 10 ( 1 ) page： 5683 2019.12

Clinical Frailty Scale Score Before ICU Admission Is Associated With Mobility Disability in Septic Patients Receiving Early Rehabilitation. Reviewed

Nakajima H, Nishikimi M, Shimizu M, Hayashi K, Inoue T, Nishida K, Takahashi K, Matsui S, Nishida Y, Matsuda N.

Crit Care Explor. Vol. 1 ( 12 ) page： e0066 2019.12

The prognostic role of β-catenin mutations in desmoid-type fibromatosis undergoing resection only: a meta-analysis of individual patient data. Reviewed

Milea J.M. Timbergen, Chiara Colombo, Michel Renckens, Hee Sung Kim, Joost van Rosmalen, Sébastien Salas, John T, Mullen, MD, Piergiuseppe Colombo, Yoshihiro Nishida, MD, Erik A.C. Wiemer, Cornelis Verhoef, Stefan Sleijfer, Alessandro Gronchi, Dirk J. Grünhagen

Ann Surg. Vol. - ( - ) page： 10.1097/SLA.0000000000003698. - 1101 2019.12

Shimizu Koki, Hamada Shunsuke, Sakai Tomohisa, Ito Shinji, Urakawa Hiroshi, Arai Eisuke, Ikuta Kunihiro, Koike Hiroshi, Ishiguro Naoki, Nishida Yoshihiro

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY Vol. 63 ( 6 ) page： 751 - 757 2019.12

Clinical Features of Thoracic Myelopathy: A Single-Center Study. Reviewed

Ando K, Imagama S, Kobayashi K, Ito K, Tsushima M, Morozumi M, Tanaka S, Machino M, Ota K, Nakashima H, Nishida Y, Ishiguro N

J Am Acad Orthop Surg Glob Res Rev. Vol. 3 ( 11 ) page： - 2019.11

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan. Reviewed

Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki Nishida, Toshifumi Ozaki

International journal of clinical oncology Vol. 24 ( 11 ) page： 1498 - 1505 2019.11

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Treatment modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative treatment. In this study, tumor characteristics of DF, transition of the treatment modality, and clinical outcome of surgical treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. METHODS: Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical treatment. RESULTS: The number of registered patients increased gradually. The frequency of surgical treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34). CONCLUSIONS: The treatment modality has shifted from surgical to conservative treatment, with risk factors for surgical treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.

DOI： 10.1007/s10147-019-01512-z

Pazopanib for progressive desmoid tumours: children, persistant effects, and cost. Reviewed

Nishida Y, Sakai T, Koike H, Ito K.

Lancet Oncol. Vol. 20 ( 10 ) page： e555 2019.10

Treatment of tenosynovial giant-cell tumour types. Reviewed

Nishida Y, Ikuta K

The Lancet. Oncology Vol. 20 ( 8 ) page： E399 - E399 2019.8

The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study Reviewed International journal

Nakamura Tomoki, Tsukushi Satoshi, Asanuma Kunihiro, Katagiri Hirohisa, Ikuta Kunihiro, Nagano Akihito, Kozawa Eiji, Yamada Satoshi, Shido Yoji, Yamada Kenji, Kawanami Katsuhisa, Ishimura Daisuke, Sudo Akihiro, Nishida Yoshihiro

CLINICAL & EXPERIMENTAL METASTASIS Vol. 36 ( 4 ) page： 343 - 350 2019.8

Language：English Publishing type：Research paper (scientific journal)

The efficacy and safety of eribulin in Japanese patients with advanced soft-tissue sarcomas (STS) have not been evaluated in a large-scale cohort study. Thus, we aimed to investigate the clinical outcome of 82 Japanese patients with STS receiving eribulin across multiple study centers retrospectively. Of 82 STS patients receiving eribulin treatment, 13 were treated for locally unresectable tumor, 46 for metastasis, and 23 for both. The primary endpoint of this study was to evaluate the efficacy of eribulin against STS. The median age was 60 years. Thirty-seven were diagnosed with L-sarcoma (leiomyosarcoma or liposarcoma) and 45 had non-L-sarcoma. The median progression-free survival (PFS) for all patients was 2.7 months, with 3.4 months in those with L-sarcoma and 2.2 months in those with non-L-sarcoma. Patients with L-sarcoma showed a better PFS than those with non-L-sarcoma. Overall, the median survival time was 11.1 months, and 12.3 months and 7.9 months in patients with L-sarcoma and non-L-sarcoma, respectively; however, there was no significant differences between the groups. The prognostic significance of PS = 0 and both existence of local and metastatic STS was evaluated by multivariate analysis. We also evaluated the overall survival (OS) in patients with undifferentiated pleomorphic sarcoma (UPS) and other non-L-sarcomas. Patients with UPS had better OS than those with the other non-L-sarcomas. In conclusion, there was a significant difference in PFS between patients with L-sarcoma and non-L-sarcoma following treatment with eribulin. The anti-tumor potential of eribulin was evident in patients with UPS.

DOI： 10.1007/s10585-019-09980-3